A study testing whether a new weekly shot from University of Colorado, Denver, tirzepatide, can protect the kidneys.
- Who can join
- Adults 18 to 65, have polycystic ovary syndrome (PCOS), BMI 27+.
- What you take
- tirzepatide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
- How long it lasts
- The full study runs about 4.3 years; your own time in it is usually shorter.
- What you get
- The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.
What this study is for
Primary condition: Autosomal Dominant Polycystic Kidney. Also studied in: Obesity.
Full scientific study title: Glucagon-Like Peptide-1 Receptor Agonist in ADPKD.
Who can join
Adults 18 to 65, have polycystic ovary syndrome (PCOS), BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- 18-65 years of age
- ADPKD diagnosis based on the modified Pei-Ravine criteria
- Body-mass index of >=27 kg/m^2
- Estimated glomerular filtration rate >= 30 mL/min/1.73m^2
- Mayo Classification of C, D, or E, calculated from a previous kidney ultrasound or MRI performed within the last 12 months
Key exclusion criteria
- Diabetes mellitus
- Tolvaptan usage or plans to initiate tolvaptan
- History of hospitalization or major surgery within the last 3 months
- Uncontrolled hypertension (systolic blood pressure > 160 or diastolic blood pressure >100 mm Hg)
- Pregnancy, lactation, or unwillingness to use adequate birth control
Where this study is enrolling
This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.
Colorado1 site
- University of Colorado - Anschutz Medical CampusAurora, Colorado
Timeline
Started enrolling: 2025-03-06. Expected completion: 2029-06-30. Last updated on ClinicalTrials.gov: 2025-05-06.
Official source
We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
